Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
August 30, 2020 02:30 ET
|
Novartis International AG
Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164 were...
Novartis announces positive results from Phase II study of LNP023 in patients with paroxysmal nocturnal hemoglobinuria (PNH)
August 29, 2020 06:30 ET
|
Novartis International AG
Oral, investigational complement factor B inhibitor LNP023 substantially improved hematological response as add-on therapy to eculizumab Seven of ten patients discontinued eculizumab and remained on...
Novartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study
August 26, 2020 01:15 ET
|
Novartis International AG
At primary analysis, ASCEMBL met its primary endpoint of significant superiority in major molecular response rate at 24 weeks for asciminib (ABL001) vs. bosutinib in patients previously treated with...
FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
August 20, 2020 13:30 ET
|
Novartis International AG
Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home, addressing significant unmet needs for people living with relapsing forms of multiple...
Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
August 05, 2020 17:01 ET
|
Novartis International AG
Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis1...
Novartis announces Kymriah® meets primary endpoint at interim analysis of pivotal study in follicular lymphoma
August 04, 2020 01:15 ET
|
Novartis International AG
Global ELARA trial demonstrated clinically meaningful benefit in patients with relapsed or refractory (r/r) follicular lymphoma (FL) as measured by complete response rate Kymriah previously received...
Novartis Cosentyx® receives EU approval for first-line systemic treatment in pediatric psoriasis
August 03, 2020 01:15 ET
|
Novartis International AG
EU approval is based on two Phase III studies showing Cosentyx® provides fast and strong skin clearance, along with significant improvement in quality of life and a favorable safety...
Novartis Adakveo® receives positive CHMP opinion for the prevention of recurrent vaso-occlusive crises in patients with sickle cell disease
July 24, 2020 07:36 ET
|
Novartis International AG
If approved, Adakveo would be the first targeted sickle cell disease therapy available for use in Europe CHMP opinion supported by data showing Adakveo significantly reduced the rate of...
Novartis réalise une excellente performance au S1. Prévisions pour 2020 confirmées dans le haut de la fourchette pour le résultat opérationnel core et dans le bas pour le chiffre d’affaires.
July 21, 2020 01:00 ET
|
Novartis International AG
En raison du Covid-19 les résultats du S1 sont plus représentatifs de la performance sous-jacente que ceux du T2, croissance de 6% (tcc1, +3% USD) du chiffre d’affaires et de 19% (tcc, +14% USD) du...
Novartis erzielte im ersten Halbjahr eine starke Performance. Die Jahresprognose 2020 für das operative Kernergebnis bzw. den Umsatz wurde am oberen bzw. unteren Ende früherer Voraussagen bestätigt.
July 21, 2020 01:00 ET
|
Novartis International AG
Aufgrund von COVID-19 sind die Ergebnisse des ersten Halbjahres repräsentativer für die zugrundeliegende Performance als die Ergebnisse des zweiten Quartals; Umsatzwachstum von 6% (kWk1, +3% USD) und...